In consideration that both MV4:11 and MOLM13 cells carry FLT3-ITD driver mutations, the induction of either apoptosis or differentiation following combined treatment with revumenib and tamibarotene without targeting constitutively active FLT3-ITD demonstrates the potential clinical relevance of this treatment approach even in this relevant AML subgroup. Here, FLT3 is linked to acute myeloid leukemia.